At a glance
ClinicalIndex Comparison RecordN/ACompleted· 93 enrolled
Drug / intervention
Medtronic Transcatheter Aortic Valve 2.0 Replacement Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Medtronic TAVR 2.0 US Clinical Study
In Brief
A clinical study evaluating Medtronic Transcatheter Aortic Valve 2.0 Replacement System for Aortic Valve Stenosis. Completed, enrolled 93 participants across 8 sites.
Detailed Summary
The study objective is to evaluate safety and efficacy of the Medtronic TAVR (Transcatheter Aortic Valve Replacement) 2.0 system in patients with severe symptomatic aortic stenosis who are considered at high through extreme risk for surgical aortic valve replacement
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAortic Valve Stenosis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartApr 2016
First PostedApr 2016
Primary CompletionNov 2016
Study CompletionDec 2021
TodayJul 2026
First PostedApr 14, 2016
Enrollment StartApr 1, 2016
Primary CompletionNov 1, 2016
Study CompletionDec 15, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 10.2 years ago
Interventions
Medtronic Transcatheter Aortic Valve 2.0 Replacement Systemdevice
Treatment of severe symptomatic aortic stenosis in subjects who are considered at high through extreme risk for surgical aortic valve replacement.